Table 1 Baseline characteristics of study patients.
From: Down Syndrome Reduces the Sedative Effect of Midazolam in Pediatric Cardiovascular Surgical Patients
variable | Total population N = 104 | Down Syndrome N = 16 | Normal N = 88 | Hypothesis for the estimation | Probabilitya |
|---|---|---|---|---|---|
Age, weeks, ±SD | 26 ± 40 | 12 ± 22 | 28 ± 42 | True difference in DS mean is less than normal | 0.93 |
Female, n, (%) | 51 (49) | 8 (50) | 43 (48) | True difference in DS prevalence is greater than normal | 0.50 |
RACHS-1b, score, ±SD | 2 (2, 2) | 2 (2, 2) | 2 (1, 2) | True difference in DS severity is greater than normal | 0.13 |
Category 1 | 10 | 2 (20%) | 8 (80%) | ||
Category 2 | 66 | 11 (16%) | 55 (84%) | ||
Category 3 | 22 | 3 (14%) | 19 (86%) | ||
Category 4 | 4 | — | 4 (100%) | ||
Category 5 | — | — | — | ||
Category 6 | 2 | — | 2 (100%) | ||
PELOD 2c, score, ±SD | 4.3 ± 1.8 | 5.6 ± 1.9 | 4.1 ± 1.8 | True difference in DS severity is greater than normal | 0.99 |
SBSd, score, (IQR) | −1 (−2, −1) | −1 (−2, −1) | −1 (−2, −1) | True difference in DS depth of sedation is less than normal | 0.35 |
Midazolam, mg/kg/day ± SD | 1.9 ± 2.1 | 3.5 ± 2.3 | 1.6 ± 2.0 | True difference in DS means is greater than normal | 0.99 |
Dexmedetomidine, μg/kg/day, ±SD | 8.2 ± 7.6 | 11.7 ± 12.3 | 7.6 ± 6.2 | True difference in DS means is greater than normal | 0.97 |
Fentanyl, mg/kg/day, ±SD | 0.2 ± 1.0 | 0.9 ± 2.4 | 0.1 ± 0.4 | True difference in DS means is greater than normal | 0.99 |
Muscle relaxant days, days, (IQR) | 0 (0, 2) | 3 (0, 5) | 0 (0, 3) | True difference in DS means is greater than normal | 0.97 |
